Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2018

View Archived Issues

Bioverativ conducts phase III trials with BIVV-009 in primary cold agglutinin disease

Green Cross LabCell and Feldan Therapeutics collaborate to develop NK cell immunotherapies

DNA repair-related biomarkers induced by alcohol have prognostic value in gastric cancer

The Salk Institute and Indivumed enter alliance to advance global cancer research

Tenax Therapeutics to develop levosimendan for PH-HFpEF

GigaGen awarded NIH grant to develop technology for rIVIG therapy

Centrexion Therapeutics' CNTX-4975 receives FDA fast track designation

ShangPharma Innovation enters multi-year strategic collaboration

Foundation Medicine, Pfizer partner to develop companion diagnostics

Jounce Therapeutics reviews its next-generation immunotherapy pipeline

U.S. priority review and E.U. accelerated assessment granted for Kymriah

FDA accepts Ruconest sBLA for review

Rxi Pharmaceuticals to focus on immuno-oncology

Gamida Cell commences phase I study of NAM-NK cells in NHL and MM

Context Therapeutics acquires Apristor from Arno Therapeutics

Final results reported from phase II study of Bekinda in IBS-D

AvantGen begins second cancer therapeutic antibody discovery program with Tanabe Research Labs

Abide Therapeutics gives an overview of their serine hydrolase-targeting products

Phase II LIBERTY study of ubenimex in PAH does not meet primary endpoint

Athenex gets positive feedback from FDA on phase III Oraxol study design

Zhejiang Palo Alto Pharmaceuticals divulges new NS5A inhibitors

FDA grants fast track designation to Aspyrian's RM-1929 in head and neck cancer

Almirall presents novel JAK inhibitors

Chinese reserachers disclose IDH1 inhibitors

Novel compounds for HBV presented by Roche

The Vanderbilt University divulges M4 receptor PAMs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...